Skip to Main Content

Advertisement

Skip Nav Destination

CD20-Tcb (RG6026), a Novel "2:1" Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Phase I First in Human Trial

Blood (2018) 132 (Supplement 1): 226.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement